{"product_id":"aav-creert2-aav-serotype-1-aav-aav1-creert2-bhv21600514","title":"AAV-CreERT2 (AAV serotype 1) AAV (AAV1-CreERT2)","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\u003cp\u003eAAV-CreERT2 (AAV serotype 1) AAV (AAV1-CreERT2) is an AAV vector packaged in AAV1 under the CMV promoter that delivers \u003cstrong\u003eCreERT2\u003c\/strong\u003e to mammalian cells. Researchers commonly use this vector for tamoxifen-inducible conditional recombination; temporal control of gene activation\/deletion.\u003c\/p\u003e\u003ch2\u003eKey elements and design rationale\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eCapsid (serotype):\u003c\/strong\u003e AAV1. broad transduction with notable activity in skeletal muscle, central nervous system (neurons), and retina.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePromoter:\u003c\/strong\u003e CMV — human cytomegalovirus immediate-early promoter; strong, broadly active in most mammalian cell types.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePayload:\u003c\/strong\u003e CreERT2 — fusion of Cre with a mutant estrogen receptor ligand-binding domain (ERT2); recombinase activity is gated by 4-hydroxytamoxifen (4-OHT) administration, allowing temporal control of recombination.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eGenome backbone:\u003c\/strong\u003e Recombinant AAV (single-stranded unless explicitly noted as scAAV) flanked by AAV2 ITRs.\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eBiological background\u003c\/h2\u003e\u003cp\u003eCreERT2 is a fusion of Cre recombinase with a triple-mutant ligand-binding domain of the estrogen receptor (ERT2). In the absence of ligand, CreERT2 is sequestered in the cytoplasm by Hsp90; binding of 4-hydroxytamoxifen (4-OHT) — but not endogenous estradiol — releases CreERT2, allowing nuclear translocation and recombination at floxed alleles.\u003c\/p\u003e\u003cp\u003eThis arrangement allows temporal control of recombination on top of the spatial control already provided by capsid tropism and promoter selectivity, which is particularly useful for studying gene function at defined developmental or experimental time points.\u003c\/p\u003e\u003cp\u003eThe CMV promoter — human cytomegalovirus immediate-early promoter; strong, broadly active in most mammalian cell types — drives expression of the payload from the AAV cassette in this product. Promoter–capsid combinations together determine where and at what level the payload is expressed.\u003c\/p\u003e\u003ch2\u003eResearch relevance and current trends\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003eCre-AAV is widely used to deliver Cre activity to brain regions or cell types without dedicated driver lines, expanding the conditional genetics toolkit.\u003c\/li\u003e\n\u003cli\u003eCombinations of intersectional approaches (Cre + Flp, or CreERT2 + tamoxifen pulses) allow finer spatial and temporal restriction of recombination.\u003c\/li\u003e\n\u003cli\u003eAAV vector engineering — including capsid evolution, capsid shuffling, and rational design — continues to expand the spectrum of accessible tissues and cell types.\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eCommon research applications\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003eTemporally controlled conditional knockout\/activation by 4-OHT\/tamoxifen.\u003c\/li\u003e\n\u003cli\u003eStage-specific activation of Cre-dependent payloads (e.g., reporters, ChR2\/DREADDs).\u003c\/li\u003e\n\u003cli\u003eLineage tracing initiated at defined time points.\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003eUse this product within experimental designs that include matched controls (capsid, promoter, dose, route) and a transduction validation step before interpreting payload-specific phenotypes.\u003c\/p\u003e\u003ch2\u003eNotes for experimental interpretation\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003eConfirm transduction efficiency in the target cell population before drawing payload-specific conclusions; reporter signal alone validates only that the vector reached and expressed in the cells.\u003c\/li\u003e\n\u003cli\u003eMatch AAV dose, capsid, promoter, and route across all conditions when comparing payload to control; differences in any of these confound payload-specific interpretation.\u003c\/li\u003e\n\u003cli\u003eAvoid repeated freeze–thaw cycles of AAV stocks — aliquot upon first thaw.\u003c\/li\u003e\n\u003cli\u003eAAV biology, including tropism, can differ between species, strains, ages, and routes — confirm in your specific system.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- Sources (internal):\n- Feil R, Wagner J, Metzger D, Chambon P. Regulation of Cre recombinase activity by mutated estrogen receptor ligand-binding domains. Biochem Biophys Res Commun. 1997. https:\/\/pubmed.ncbi.nlm.nih.gov\/9299402\/\n- Indra AK, et al. Temporally-controlled site-specific mutagenesis in the basal layer of the epidermis: comparison of the recombinase activity of the tamoxifen-inducible Cre-ER(T) and Cre-ER(T2) recombinases. Nucleic Acids Res. 1999. https:\/\/academic.oup.com\/nar\/article\/27\/22\/4324\/2902352\n- Schultz BR, Chamberlain JS. Recombinant adeno-associated virus transduction and integration. Mol Ther. 2008. https:\/\/www.cell.com\/molecular-therapy-family\/molecular-therapy\/fulltext\/S1525-0016(16)33063-5\n--\u003e","brand":"Vector Biolabs","offers":[{"title":"AAV1 \/ 1x10^13 GC\/ml \/ 20 µL","offer_id":53286504137069,"sku":"7110","price":495.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/www.ebiohippo.com\/products\/aav-creert2-aav-serotype-1-aav-aav1-creert2-bhv21600514","provider":"BioHippo","version":"1.0","type":"link"}